"Using Artificial Intelligence to Unravel Ancient Healing Secrets"

Aion Therapeutic is an emerging unique international pharmaceutical company specializing in joining together the healing powers of medical cannabis and medicinal mushroom compounds creating a new class of therapeutics which we believe will lead to a paradigm shift in healthcare globally.

BREAKING NEWS: Aion Therapeutic Opening First Psychiatrist Supervised International Center for Psychedelic Psychiatry Specializing In Psylocibin and Cannabinoid Treatments in Jamaica. Aion Therapeutic Opening First Psychiatrist Supervised International Center for Psychedelic Psychiatry Specializing In Psylocibin and Cannabinoid Treatments in Jamaica.Aion Therapeutic Opening First Psychiatrist Supervised International Center for Psychedelic Psychiatry Specializing In Psylocibin and Cannabinoid Treatments in Jamaica.Aion Therapeutic Opening First Psychiatrist Supervised International Center for Psychedelic Psychiatry Specializing In Psylocibin and Cannabinoid Treatments in Jamaica.Aion Therapeutic Opening First Psychiatrist Supervised International Center for Psychedelic Psychiatry Specializing In Psylocibin and Cannabinoid Treatments in Jamaica.


In the United States, of the top 150 prescription drugs, at least 118 are based on natural sources:



Our Markets

300 million People Globally Affected By Depression

$60 Billion Market in 2020


10 million People Globally Die of Cancer Every Year

$100 Billion Market in 2020


1 Billion + People Globally Get Viral Infections every year

$59.9 Billion Market in 2020


2.7 Billion People are Obese, Nearly 30% of the worlds population

$2 Trillion Market in 2018


350 Million People Globally are affected by Arthritis
and Joint Diseases

$93.88 Billion Market in 2019


Aion Therapeutic combines healing compounds from medical cannabis and medicinal mushrooms to create combinatorial therapeutic pharmaceuticals, nutraceuticals, and cosmeceuticals.

LEVERAGING ARTIFICIAL INTELLIGENCE FOR OUR THERAPEUTIC DISCOVERIES

Aion Therapeutic Processes and Analyzes Plant & Mushroom Genetics, Phenotypes and Biochemistry With Proprietary Artificial Intelligence Techniques.

We will utilize Artificial Intelligence Techniques to create disease specific patentable medical cannabis/mushroom formulation treatments to create Personalized Medicine

docsplace

Genome Based Personalized Medicine

Aion Therapeutic utilizes artificial intelligence techniques to analyze patient specific genomic data to properly triage patients into the correct therapeutic formulations specifically designed for an individual patient thereby bringing medical cannabis and medicinal mushrooms treatments into the realm of true personalized medicine.

Our Team


Stephen D. Barnhill, M.D.
Executive Chairman

Cannabinoid & Mushroom Medicine, Chairman and CEO, AI Pharmaceuticals*,
Former Founder, Chairman, CEO of BCL Laboratories (Acquired by Quest Diagnostics).
Chairman, CEO Doc’s Place Wellness Resort, Chairman, CEO Apollon Formularies (UK)
Chairman, CEO Apollon Formularies (US) President and Director Apollon Formularies Jamaica.
Inventor on 40+ Award Winning International Patents on Artificial Intelligence & Cancer Diagnostics
*AI Pharmaceuticals, Jamaican subsidiary owned by Aion Therapeutic

Winston De La Haye, MD
Medical Director, Psychedelic Psychiatry

Clinical Director, Addiction Treatment Services Unit University Hospital of the West Indies (UWI).
Johns Hopkins University, Fulbright Fellowship Mental Health and Substance Abuse.
Johns Hopkins University Master of Public Health (MPH).
Former Chief Medical Officer, Ministry of Health, Jamaica
Deputy Dean, Faculty of Medical Science, (UWI), Mona Campus

Anthony J. Hall, MDCM, FACS, FAANS
Medical Director

Neurosurgeon, Board Certified Brain and Spine Surgeon,
Doctor of Medicine degree from McGill University Faculty of Medicine,
Associate Professor, Florida Int. Univ. College of Medicine,
One of the first five physicians Certified by the state of Florida to recommend medical cannabis.
Dr. De La Haye

Herbert Fritsche, Ph.D.
Chief Science Officer

Former Professor & Director of Clinical Chemistry MD Anderson Cancer Center (40+ years)
Consultant/Advisor to the National Cancer Institute (NCI), 200+ Peer Reviewed Publications,
Johnson & Johnson Award for Outstanding Research & Contributions to Clinical Biochemsitry,
Morton K Schwartz Award Outstanding Cancer Research,
World Renown Expert in Cancer Diagnostics, Clinical Chemistry and Laboratory Medicine

Paul Burke
President, AI Pharmaceuticals*

Former General Secretary of the Jamaican People's National Party (PNP) from 2014-2016
Chairman and Founding Member of the National Alliance for the Legalization of Ganja
Project Manager, Founding Member of the Cannabis Commercial and Medicinal Task Force Programme
Director and Founding Member of the Ganja Growers and Producers Association of Jamaica
Chairman of the Jamaican Wellness and Health Network.

*AI Pharmaceuticals, Jamaican subsidiary owned by Aion Therapeutic

Graham Simmonds
CEO, Aion Therapeutic

20 years experience in public company management and developing businesses.
Chairman, Plant-Based Investment Corp (CSE: PBIC),
Executive Chair, Bhang Inc. (CSE: BHNG)



Timeline of Theurapeutics Development

Aion Therapeutic, over the past year, has significantly advanced our timeline of product development and patient treatments with many of our therapeutics now ready for patients.

docsplace


Aion Health and Wellness Resort

Patients from Jamaica and around the world are welcome to our health and wellness resort in Negril Jamaica.

To make an appointment with one of our team physicians for treatment or for more information fill out form below.

docsplace